Pierre Van Damme1, Chris J L M Meijer2, Dorothee Kieninger3, Anne Schuyleman4, Stephane Thomas5, Alain Luxembourg6, Martine Baudin7. 1. Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Universiteitsplein 1, 2610 WIlrijk, Belgium. Electronic address: pierre.vandamme@uantwerpen.be. 2. VU University Medical Centre, De Boelelaan 1117, 1084HV Amsterdam, The Netherlands. Electronic address: CJLM.Meijer@vumc.nl. 3. Centre for Clinical Trials, Children's Hospital, Universitätsmedizin, Mainz, Germany. Electronic address: Dorothee.kieninger@unimedizin-mainz.de. 4. Sanofi Pasteur MSD, Lyon, France. Electronic address: ASchuyleman@spmsd.com. 5. Sanofi Pasteur MSD, Lyon, France. Electronic address: SThomas@spmsd.com. 6. Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: alain_luxembourg@merck.com. 7. Sanofi Pasteur MSD, Lyon, France. Electronic address: baudinmartine@yahoo.fr.
Abstract
BACKGROUND: A nine-valent human papilloma virus (9vHPV) vaccine has been developed to prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV (qHPV) vaccine) as well as to five additional oncogenic HPV types (HPV 31/33/45/52/58). The 9vHPV vaccine has the potential to prevent 90% of cervical cancers, HPV-related anal, vaginal and vulval cancers and anogenital warts. We compared the immunogenicity and safety of the 9vHPV vaccine versus the qHPV vaccine in 16-26-year-old men. METHODS:Participants (N=500) were randomised to receive 9vHPV or qHPV vaccines on day 1, month 2 and month 6. Serology testing was performed on day 1 and month 7. HPV type-specific antibody titres (anti-HPV 6/11/16/18/31/33/45/52/58) were determined by competitive Luminex immunoassay and expressed as geometric mean titres and seroconversion rates. Vaccine safety was also assessed. RESULTS: The HPV 6/11/16/18 immune responses elicited by the 9vHPV vaccine were comparable with those elicited by the qHPV vaccine. All participants receiving the 9vHPV vaccine seroconverted for HPV 31/33/45/52/58. The 9vHPV and qHPV vaccines showed comparable safety profiles. CONCLUSIONS: In addition to immune responses to HPV 31/33/45/52/58, a three-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in men aged 16-26years. The safety profile was also similar for the two vaccines. The results from this study support extending the efficacy findings with qHPV vaccine to 9vHPV vaccine in men aged 16-26years. NCT02114385.
RCT Entities:
BACKGROUND: A nine-valent human papilloma virus (9vHPV) vaccine has been developed to prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV (qHPV) vaccine) as well as to five additional oncogenic HPV types (HPV 31/33/45/52/58). The 9vHPV vaccine has the potential to prevent 90% of cervical cancers, HPV-related anal, vaginal and vulval cancers and anogenital warts. We compared the immunogenicity and safety of the 9vHPV vaccine versus the qHPV vaccine in 16-26-year-old men. METHODS:Participants (N=500) were randomised to receive 9vHPV or qHPV vaccines on day 1, month 2 and month 6. Serology testing was performed on day 1 and month 7. HPV type-specific antibody titres (anti-HPV 6/11/16/18/31/33/45/52/58) were determined by competitive Luminex immunoassay and expressed as geometric mean titres and seroconversion rates. Vaccine safety was also assessed. RESULTS: The HPV 6/11/16/18 immune responses elicited by the 9vHPV vaccine were comparable with those elicited by the qHPV vaccine. All participants receiving the 9vHPV vaccine seroconverted for HPV 31/33/45/52/58. The 9vHPV and qHPV vaccines showed comparable safety profiles. CONCLUSIONS: In addition to immune responses to HPV 31/33/45/52/58, a three-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in men aged 16-26years. The safety profile was also similar for the two vaccines. The results from this study support extending the efficacy findings with qHPV vaccine to 9vHPV vaccine in men aged 16-26years. NCT02114385.
Authors: Hanna Bergman; Brian S Buckley; Gemma Villanueva; Jennifer Petkovic; Chantelle Garritty; Vittoria Lutje; Alina Ximena Riveros-Balta; Nicola Low; Nicholas Henschke Journal: Cochrane Database Syst Rev Date: 2019-11-22
Authors: Ross D Cranston; Alex Carballo-Diéguez; Holly Gundacker; Barbra A Richardson; Rebecca Giguere; Curtis Dolezal; Aaron Siegel; Ratiya P KunjaraNaAyudhya; Kailazarid Gomez; Jeanna M Piper; Javier R Lama; Ian McGowan Journal: Int J STD AIDS Date: 2018-10-18 Impact factor: 1.359
Authors: Evy Yunihastuti; Nipat Teeratakulpisarn; Wifanto Saditya Jeo; Hanny Nilasari; Lisnawati Rachmadi; I Ketut Agus Somia; Made Dewi Dian Sukmawati; Komang Agus Trisna Amijaya; Ilias A Yee; Nany Hairunisa; Piranun Hongchookiat; Deondara Trachunthong; Tippawan Pankam; Siriporn Nonenoy; Reshmie Ramautarsing; Iskandar Azwa; Tuti P Merati; Praphan Phanuphak; Nittaya Phanuphak; Joel M Palefsky Journal: AIDS Date: 2020-11-01 Impact factor: 4.632